The “Real world Outcomes across the AD spectrum for better care: Multi-modal data Access Platform” (ROADMAP) project’s Work Package 2 (WP2) “Outcome Definition” has delivered its report on: “D2.1 First list of priority Real World Evidence relevant outcomes for Alzheimer’s disease” to the Innovative Medicines Initiative.
This list represents a first step to creating an overview of the ‘universe’ of outcomes across the spectrum of Alzheimer’s disease.
The final list will consist of evidence relevant to a wide range of stakeholders, including people with dementia, carers, clinicians, scientists, policy makers and others.
During the development the group has drawn upon findings from literature and followed consultation with some of its partners within the Consortium.
Over the lifespan of ROADMAP WP2’s research activities, outcomes will be added, removed and ranked. In the next stages of work, outcomes will be prioritised and criteria for meaningful delay in disease progression will be agreed upon. This will be achieved through the synthesis of findings from systematic reviews, stakeholder surveys, priority-setting workshops and on-going collaboration within the Consortium.
Find the deliverable here: http://roadmap-alzheimer.org/downloads/deliverables/